Figure 1

DNA methylation and serum levels of IGFBP1 in Swedish men with normal glucose tolerance and type 2 diabetes. (A) IGFBP1 DNA methylation levels at each of the six CpG sites in patients with newly diagnosed type 2 diabetes and in patients undergoing treatment were significantly higher compared with those in non-diabetic control subjects (P < 0.001 for all comparisons with non-diabetic subjects). (B) Combining all six CpG sites together as total, significantly increased DNA methylation levels of the IGFBP1 gene in newly diagnosed and treated type 2 diabetes patients in comparison with the controls were found (18.9%, 19.8% and 16.9%, respectively, P < 0.001 for both type 2 diabetes group vs. controls.) (C) Serum IGFBP-1 levels were significantly higher in non-diabetic control subjects than in both newly diagnosed and treated patients with type 2 diabetes. P values: * < 0.05, *** < 0.001. IGFBP-1, insulin-like growth factor binding protein-1; NGT, normal glucose tolerance; T2D, type 2 diabetes.